Compare Heron Therapeutics Inc (HRTX) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Northrop Grumman Corporation — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Northrop Grumman Corporation trades at $511.45 (market cap $74.42B). The key difference: Northrop Grumman Corporation is far larger — about 813.7× Heron Therapeutics Inc's market cap, and Northrop Grumman Corporation pays a 1.79% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | NOC | |
|---|---|---|
Market Cap | $91.46M | $74.42B |
Sector | Health | Industrials |
52-Week High | $1.96 | $768.02 |
52-Week Low | $0.39 | $496.02 |
Enterprise Value | $189.36M | $88.65B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Northrop Grumman (NOC) trades at $524.14, up 0.49% with a bearish technical signal despite strong fundamentals. The company shows consistent earnings beats, with Q1 2026 EPS of $6.14 exceeding expectations of $6.06. Recent news highlights defense budget optimism and a $312.3M Navy contract for electronic warfare systems. Technical indicators show RSI at oversold levels near support at $518, while moving averages signal bearish momentum.
The investment outlook remains positive with analyst consensus at Buy (57% of 35 analysts) and a $655 price target representing 25% upside. Risks include execution challenges in defense programs and potential margin pressure. Strong cash flow generation and a $96B backlog support long-term growth, though near-term technical weakness may present entry opportunities for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
